Envoy Medical (COCH) Net Income towards Common Stockholders (2021 - 2026)

Envoy Medical has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$7.3 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 4.75% year-over-year to -$7.3 million; the TTM figure through Jun 2026 stood at -$28.5 million (down 0.9% YoY), while the FY2025 annual figure was -$28.7 million, down 2.46% from the prior year.
• Net Income towards Common Stockholders came in at -$7.3 million for Q2 2026 at Envoy Medical, down from -$5.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $18.0 million in Q2 2022 to a low of -$13.3 million in Q1 2023.
• Average Net Income towards Common Stockholders over 5 years is -$4.1 million, with a median of -$6.6 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders surged 5971.24% in 2022 and sank 624.29% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$11.5 million in 2022, then surged by 45.34% to -$6.3 million in 2023, then declined by 22.53% to -$7.7 million in 2024, then slipped by 0.66% to -$7.7 million in 2025, then gained by 6.01% to -$7.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.3 million in Q2 2026, -$5.7 million in Q1 2026, and -$7.7 million in Q4 2025.